vs

Side-by-side financial comparison of Greystone Housing Impact Investors LP (GHI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Greystone Housing Impact Investors LP is the larger business by last-quarter revenue ($15.0M vs $12.5M, roughly 1.2× Avidity Biosciences, Inc.). Greystone Housing Impact Investors LP runs the higher net margin — -38.9% vs -1398.3%, a 1359.4% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -33.6%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -18.1%).

Greystone Housing Impact Investors LP is a publicly traded real estate investment partnership focused on acquiring, owning, and managing affordable and workforce multifamily housing properties across the United States. It prioritizes investments that generate stable long-term returns while expanding housing access for low and middle income communities.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

GHI vs RNA — Head-to-Head

Bigger by revenue
GHI
GHI
1.2× larger
GHI
$15.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+467.6% gap
RNA
434.0%
-33.6%
GHI
Higher net margin
GHI
GHI
1359.4% more per $
GHI
-38.9%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-18.1%
GHI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
GHI
GHI
RNA
RNA
Revenue
$15.0M
$12.5M
Net Profit
$-5.8M
$-174.4M
Gross Margin
Operating Margin
-33.4%
-1513.5%
Net Margin
-38.9%
-1398.3%
Revenue YoY
-33.6%
434.0%
Net Profit YoY
-157.6%
-117.0%
EPS (diluted)
$-0.31
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GHI
GHI
RNA
RNA
Q4 25
$15.0M
Q3 25
$21.7M
$12.5M
Q2 25
$23.6M
$3.8M
Q1 25
$25.1M
$1.6M
Q4 24
$22.6M
$3.0M
Q3 24
$24.3M
$2.3M
Q2 24
$22.0M
$2.0M
Q1 24
$22.4M
$3.5M
Net Profit
GHI
GHI
RNA
RNA
Q4 25
$-5.8M
Q3 25
$2.0M
$-174.4M
Q2 25
$-7.1M
$-157.3M
Q1 25
$3.3M
$-115.8M
Q4 24
$10.1M
$-102.3M
Q3 24
$-4.6M
$-80.4M
Q2 24
$5.2M
$-70.8M
Q1 24
$10.6M
$-68.9M
Operating Margin
GHI
GHI
RNA
RNA
Q4 25
-33.4%
Q3 25
9.1%
-1513.5%
Q2 25
-30.0%
-4448.7%
Q1 25
13.2%
-8360.9%
Q4 24
45.0%
-4069.6%
Q3 24
-19.0%
-4200.9%
Q2 24
23.6%
-4040.4%
Q1 24
47.6%
-2178.6%
Net Margin
GHI
GHI
RNA
RNA
Q4 25
-38.9%
Q3 25
9.1%
-1398.3%
Q2 25
-30.0%
-4089.3%
Q1 25
13.2%
-7360.0%
Q4 24
44.9%
-3439.5%
Q3 24
-19.0%
-3441.7%
Q2 24
23.6%
-3461.8%
Q1 24
47.6%
-1943.4%
EPS (diluted)
GHI
GHI
RNA
RNA
Q4 25
$-0.31
Q3 25
$0.03
$-1.27
Q2 25
$-0.35
$-1.21
Q1 25
$0.11
$-0.90
Q4 24
$0.38
$-0.80
Q3 24
$-0.23
$-0.65
Q2 24
$0.19
$-0.65
Q1 24
$0.42
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GHI
GHI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$39.5M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
Total Assets
$1.5B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GHI
GHI
RNA
RNA
Q4 25
$39.5M
Q3 25
$36.2M
$350.2M
Q2 25
$47.5M
$243.9M
Q1 25
$51.4M
$254.2M
Q4 24
$14.7M
$219.9M
Q3 24
$37.4M
$370.2M
Q2 24
$34.0M
$575.8M
Q1 24
$56.3M
$471.4M
Stockholders' Equity
GHI
GHI
RNA
RNA
Q4 25
Q3 25
$1.9B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$1.2B
Q1 24
$830.9M
Total Assets
GHI
GHI
RNA
RNA
Q4 25
$1.5B
Q3 25
$1.5B
$2.1B
Q2 25
$1.5B
$1.4B
Q1 25
$1.5B
$1.5B
Q4 24
$1.6B
$1.6B
Q3 24
$1.5B
$1.6B
Q2 24
$1.5B
$1.3B
Q1 24
$1.5B
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GHI
GHI
RNA
RNA
Operating Cash FlowLast quarter
$37.5M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GHI
GHI
RNA
RNA
Q4 25
$37.5M
Q3 25
$8.4M
$-156.2M
Q2 25
$10.2M
$-199.7M
Q1 25
$10.3M
$-124.8M
Q4 24
$18.0M
$-99.9M
Q3 24
$4.9M
$-65.6M
Q2 24
$5.1M
$-65.0M
Q1 24
$3.4M
$-70.4M
Free Cash Flow
GHI
GHI
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
GHI
GHI
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
GHI
GHI
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
GHI
GHI
RNA
RNA
Q4 25
Q3 25
4.25×
Q2 25
Q1 25
3.11×
Q4 24
1.78×
Q3 24
Q2 24
0.98×
Q1 24
0.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons